Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
34.14
+0.41 (1.22%)
At close: Apr 28, 2026, 4:00 PM EDT
33.61
-0.53 (-1.55%)
After-hours: Apr 28, 2026, 5:26 PM EDT
Alkermes Revenue
In the year 2025, Alkermes had annual revenue of $1.48B, down -5.25%. Alkermes had revenue of $384.55M in the quarter ending December 31, 2025, a decrease of -10.57%.
Revenue (ttm)
$1.48B
Revenue Growth
-5.25%
P/S Ratio
3.85
Revenue / Employee
$719,951
Employees
2,050
Market Cap
5.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.48B | -81.73M | -5.25% |
| Dec 31, 2024 | 1.56B | -105.78M | -6.36% |
| Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
| Dec 31, 2022 | 1.11B | -61.95M | -5.28% |
| Dec 31, 2021 | 1.17B | 134.99M | 13.00% |
| Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
| Dec 31, 2019 | 1.17B | 76.68M | 7.01% |
| Dec 31, 2018 | 1.09B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| Amneal Pharmaceuticals | 3.02B |
| Neurocrine Biosciences | 2.86B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
| Prestige Consumer Healthcare | 1.10B |
| Supernus Pharmaceuticals | 718.95M |
ALKS News
- 7 days ago - Alkermes to Report First Quarter Financial Results on May 5, 2026 - Business Wire
- 12 days ago - Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting - Business Wire
- 14 days ago - Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry - Business Wire
- 27 days ago - Top 2 Health Care Stocks That May Implode In April - Benzinga
- 27 days ago - Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 - Business Wire
- 6 weeks ago - Alkermes Transcript: Stifel 2026 Virtual CNS Forum - Transcripts
- 6 weeks ago - Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program - Business Wire
- 7 weeks ago - Alkermes to Present at the Stifel 2026 Virtual CNS Forum - Business Wire